NCT04837209View on ClinicalTrials.gov

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 21, 2021

Primary Completion Date

February 1, 2027

Study Completion Date

December 1, 2029

Conditions
Breast CancerTriple Negative Breast Cancer
Interventions
DRUG

Niraparib

Capsule, taken by mouth

DRUG

Dostarlimab

Intravenous infusion

RADIATION

Radiation therapy

Radio Therapy

Trial Locations (4)

19104

University of Pennsylvania Abramson Cancer Center, Philadelphia

20016

Sibley Memorial Hospital, Washington D.C.

27710

Duke University Medical Center, Durham

02114

Massachusetts General Hospital Cancer Center, Boston

Sponsors

Collaborators (1)

Duke University
All Listed Sponsors
collaborator

Sibley Memorial Hospital

UNKNOWN

collaborator

Duke University

OTHER

collaborator

University of Pennsylvania

OTHER

lead

Massachusetts General Hospital

OTHER

NCT04837209 - Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter